Literature DB >> 8101679

T cell receptor beta chain gene polymorphisms in Graves' disease.

A P Pickerill1, P F Watson, N Tandon, A P Weetman.   

Abstract

Graves' disease, or subgroups of such patients with thyroglobulin antibodies or HLA-DR3, have been associated with a restriction fragment length polymorphism of the T cell receptor beta chain constant region gene but not all studies are in agreement. We have examined 58 patients with Graves' disease and found no abnormal distribution of this polymorphism compared to 33 controls. There was also no significant association with the presence of thyroglobulin antibodies or HLA-DR3, even when the results were pooled with previously collected data (N = 90 patients with TG antibody results and N = 128 patients with HLA-DR types). We also found no abnormal distribution of three polymorphisms of the T cell receptor beta chain variable region genes, using probes which span over 600 kb of this complex. These results argue against an association of these allelic variations of the T cell receptor beta chain with Graves' disease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8101679     DOI: 10.1530/acta.0.1280499

Source DB:  PubMed          Journal:  Acta Endocrinol (Copenh)        ISSN: 0001-5598


  3 in total

1.  A new Graves disease-susceptibility locus maps to chromosome 20q11.2. International Consortium for the Genetics of Autoimmune Thyroid Disease.

Authors:  Y Tomer; G Barbesino; D A Greenberg; E Concepcion; T F Davies
Journal:  Am J Hum Genet       Date:  1998-12       Impact factor: 11.025

2.  Immunogenetic mechanisms leading to thyroid autoimmunity: recent advances in identifying susceptibility genes and regions.

Authors:  Oliver J Brand; Stephen C L Gough
Journal:  Curr Genomics       Date:  2011-12       Impact factor: 2.236

3.  Estrogen receptor alpha dinucleotide repeat polymorphism in Japanese patients with autoimmune thyroid diseases.

Authors:  Y Ban; M Taniyama; T Tozaki; M Tomita; Y Ban
Journal:  BMC Med Genet       Date:  2000-11-23       Impact factor: 2.103

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.